

LIDDS Nomination committee proposes New Members of the Board

UPPSALA, SWEDEN - LIDDS AB (publ) announces today that the Nomination Committee proposes Daniel Lifveredson, Torbjörn Browall and Lars-Inge Sjöqvist as new members of LIDDS Board of Directors. The proposal is presented to the Extraordinary Meeting of Shareholders on 9 January 2024.

The Nomination Committee proposes that three ordinary Board members and one deputy Member are appointed for the period until the end of the next Annual General Meeting. The Nomination Committee proposes that the annual remuneration to be paid to the Board of Directors shall total SEK 225,000, to be allocated with SEK 112,500 to the Chairman of the Board and with SEK 56,250 each to other Board members.

The Nomination Committee proposes election of Daniel Lifveredson, Torbjörn Browall and Lars-Inge Sjöqvist as ordinary Board members and Bengt Viterius as deputy member for the period until the end of the next Annual General Meeting. Daniel Lifveredson is proposed as the new chairman of the Board.

Torbjörn Browall has had leading roles within SKF, Gränges, Volvo and Gnosjögruppen and has during the last 15 years been active in entrepreneurial companies within different sectors. Torbjörn was born in 1962 and has a Bachelor of Science in Economics from Gothenburg University. He is independent in relation to LIDDS AB and its management and to major shareholders in the company.

Lars-Inge Sjöqvist is the owner of Actionstep AB and has more than 30 years of experience from business and product development and management in roles such as CEO of Gapwaves AB (publ), Vice President and CEO of Semcon AB (publ) and Chairman of Trebax AB and Kildal Antenn AB. Lars-Inge was born in 1962 and is a civil engineer from Chalmers University, Gothenburg. He is independent in relation to LIDDS AB and its management and to major shareholders in the company.

Daniel Lifveredson was member of the Board in LIDDS between 2017 and 2023. He is the CEO and owner of Excore AB, active in advising on transactions for medium-sized companies. Daniel was born in 1976 and has a Master of Science in Industrial Economics from Chalmers University of Technology, Gothenburg. He is independent in relation to LIDDS AB and its management and to major shareholders in the company.


Bengt Viterius has had different roles within health care services such as HR and marketing within Carema. Bengt was born in 1945. He is independent in relation to LIDDS AB and its management and to major shareholders in the company.


For additional information, please contact

Jenni Björnulfson, CEO and CFO Phone: +46 (0)70 855 38 05

E-mail: jenni.bjornulfson@liddspharma.com

LIDDS' Certified Adviser is Redeye AB







LIDDS in brief:

LIDDS is a Swedish drug delivery company based on the proprietary technology NanoZolid®. With NanoZolid®, LIDDS can formulate drugs for local/intratumoral administration, with a maintained and controlled release for up to six months. The technology is versatile, can be used across different drug classes and can solve problems within many indication areas, mainly within oncology. LIDDS offers the NanoZolid® technology to partners and has developed its own pipeline focused on oncology, where the technology enables delivery of a local and high drug dose, administered over time with very limited side effects. LIDDS has a broad pipeline with several projects in clinical development, both in early and late-stage clinical phase, and projects about to enter clinical development. The company is listed on Nasdaq First North Growth Market.

Attachments

LIDDS Nomination committee proposes New Members of the Board